

# JUNE 18, 2020

## TEXAS HEALTHCARE AND BIOSCIENCE SUMMIT



### THE CHALLENGES OF SUCCESS: CONNECTING THE DOTS TO FIND THE NEXT CURE

The Summit will provide an in-depth look at the steps involved in creating vaccines, drugs and therapeutics. The “Bench to the Marketplace” concept is a difficult and timely process, often taking years or even decades, to achieve. Strong public health policies can help to encourage innovation throughout the process, while providing solutions and improved patients health outcomes.

Thank you for joining us today, and being a part of the conversations with state and national policy leaders and key life science experts on the challenges the life science industry faces when responding to a global health crisis, and how it affects the healthcare system and healthcare supply chain, patients with other illnesses, and the economy.

# JOIN THE CONVERSATION

## SOCIAL MEDIA GUIDE

---



**Texas Healthcare and  
Bioscience Institute**

**#THBISUMMIT  
#Innovation**



**@TxHBI**

**#txbioscience  
#txlege**

---

## TABLE OF CONTENTS

About THBI.....	4
THBI Board Members .....	5
Summit Program Schedule.....	6
Speaker, Panelist and Moderator Bios.....	8
Summit Sponsors .....	16



The Texas Healthcare & Bioscience Institute (THBI) is the leading voice of the Texas healthcare and bioscience industries. THBI is an advocacy organization focused on public policy in the life sciences and healthcare and bioscience industries. Our work extends beyond the Capitol as we partner with numerous economic development organizations across the state to recruit and retain jobs for Texas.

Our membership consists of biopharmaceutical companies, research institutions, medical device companies, economic development entities and service companies providing unparalleled networking and synergy to effectively address the public policy needs of Texas' growing life sciences community.

Become a THBI member to be a part of the important policy initiatives our industry will be working on during the 87th Legislative Session and THBI's 2020-2021 programming schedule, including a series of member-only policy events. Contact [info@thbi.com](mailto:info@thbi.com) to learn more. Visit [www.thbi.com](http://www.thbi.com) to stay informed about upcoming events and opportunities.



# THBI BOARD OF DIRECTORS

## THANK YOU TO OUR BOARD MEMBERS FOR YOUR CONTINUED SUPPORT

### CHAIRMAN

**David R. Margrave**

*Trinita Life Science Advisors*

### VICE CHAIRMAN

**Andrea Giuffrida, Ph.D.**

*UT Health San Antonio*

### SECRETARY

**Holly Jacques Turner**

*Merck*

### TREASURER

**Bradley Westmoreland**

*Genentech, Inc.*

### PRESIDENT AND CEO

**Tom Kowalski**

*Texas Healthcare and Bioscience Institute*

**Jeff Buel**

*Johnson & Johnson*

**Mark Moreno**

*The University of Texas  
MD Anderson Cancer Center*

**Ryan Garofalo**

*PhRMA*

**Amber Pearce**

*Pfizer*

**Holli Hill**

*Novartis Pharmaceuticals*

**Joan Solem**

*Eli Lilly & Company*

**Kyle Kamrath**

*Vertex Pharmaceuticals*

**Jeffrey L. Wade**

*Lexicon Pharmaceuticals*

# SCHEDULE OF EVENTS

JUNE 18, 2020

12:00 pm	<b>WELCOME</b> <ul style="list-style-type: none"><li>• <b>Tom Kowalski</b>, President and CEO, Texas Healthcare and Bioscience Institute</li></ul>
12:05 pm	<b>OPENING KEYNOTE</b> <ul style="list-style-type: none"><li>• <b>The Honorable Tom Oliverson, M.D.</b>, Texas House of Representatives</li></ul>
12:35 pm	<b>INNOVATION TO CURES: WHAT ARE THE CHALLENGES AND HOW DO WE RESPOND TO WORLDWIDE PANDEMICS?</b> <p>The pathway to discovery is faced with many obstacles. This panel will focus on the steps and policies necessary to bring discoveries to the patient, from medications used to treat medical conditions and illnesses, to vaccines created to stop highly contagious viruses.</p> <ul style="list-style-type: none"><li>• <b>The Honorable Kelly Hancock</b>, Texas State Senator, Chair, Senate Committee on Business &amp; Commerce</li><li>• <b>Dr. David Lakey</b>, Vice Chancellor for Health Affairs and Chief Medical Officer, The University of Texas System</li><li>• <b>Dr. Ed Rudnic</b>, CEO, DisperSol Technologies</li><li>• <b>Dr. Larry Schlesinger</b>, President and CEO, Texas Biomedical Research Institute</li><li>• <b>Moderator: Tom Kowalski</b>, President and CEO, Texas Healthcare and Bioscience Institute</li></ul>
1:30 pm	<b>KEYNOTE</b> <ul style="list-style-type: none"><li>• <b>Dr. Kristofor Langlais</b>, Biomedical Policy Analyst and Genomics Program Lead with the National Institutes of Health (NIH)</li></ul>

**2:05 pm**

### **THE DYNAMIC IMPACT OF RESEARCH AND TEXAS INSTITUTIONS**

Bench to the marketplace starts with research and strong collaborative partners. This panel will feature a conversation on connecting the dots between research and bringing a drug, vaccine or medical device to the marketplace. Additionally, we will explore the nature of how academic research and private partnerships shape the future of innovation in the life sciences industry.

- **Dr. Amr Elnashai**, Vice President/Vice Chancellor for Research and Technology Transfer, University of Houston
- **The Honorable Kent R. Hance**, Hance Scarborough, L.L.P.
- **The Honorable John Zerwas, M.D.**, Executive Vice Chancellor for Health Affairs, The University of Texas System
- **Moderator: Barry Burgdorf**, Attorney, Pillsbury

**2:50 pm**

### **CLOSING KEYNOTE**

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. PhRMA and its member companies are not only using their scientific expertise to find ways to diagnose, treat and prevent infections from the virus, they are also providing financial support and in-kind donations to organizations and collaborating with U.S. and global health authorities to combat this global public health emergency.

- **Lori M. Reilly, Esq.**, Chief Operating Officer, PhRMA

**3:08 pm**

### **CLOSING REMARKS**

- **Tom Kowalski**, President and CEO, Texas Healthcare and Bioscience Institute

# SPEAKERS, PANELISTS AND MODERATORS

IN ALPHABETICAL ORDER



## **BARRY BURGDORF**

Attorney

Pillsbury Winthrop Shaw Pittman

Barry Burgdorf is Special Counsel at Pillsbury, a global law firm of more than 700 lawyers. Located in Austin, Barry maintains a multifaceted practice handling corporate, technology and IP matters. He primarily focuses on the life sciences/biotech, healthcare, IT & software and other technology markets. He also maintains an active practice in the higher education space.

Barry has served as general counsel, outside counsel and as part of the corporate suite for both a life sciences and biotech venture capital company, providing him a holistic view and inside track on client needs and problem-solving. Following time as a business litigator and then corporate securities and M&A partner at Vinson & Elkins, Barry took the job of Vice Chancellor and General Counsel of University of Texas System, where for eight years he served as a key member of the leadership team and oversaw areas ranging from legal to real estate to IT security and importantly technology transfer.

His experience with federal agencies and contracting is wide and varied and includes the Department of Homeland Security, Drug Enforcement Agency, Border Patrol, Department of Education, Department of Energy, Department of Justice and the National Institute of Health.





## **DR. AMR ELNASHAI, FREng**

**Vice Chancellor/Vice President for Research  
and Technology Transfer  
University of Houston**

Fellow of the British Royal Academy of Engineering, Amr Elnashai is the Vice Chancellor/Vice President for Research and Technology Transfer at the University of Houston.

Previously, Amr served as Dean of Engineering at the Pennsylvania State University, where he held the Harold and Inge Marcus Chair of Engineering. He has been visiting professor at the University of Surrey, UK, since 1997. Other visiting professor appointments include the University of Tokyo, the University of Southern California, and the European School for Advanced Studies in Reduction of Seismic Risk, Italy.

Amr is founder and editor-in-chief of the Journal of Earthquake Engineering; a member of the drafting panel of the European design codes; past chair of the UK earthquake engineering association; and a member of the Council of the UK Institution of Structural Engineers.

Amr's technical interests are multi-resolution distributed analytical simulations, network analysis, large-scale hybrid testing and field investigations of the response of complex networks and structures to earthquakes. He has produced over 260 research publications; research reports; three books and several book chapters; magazine articles; and earthquake field investigation reports.

Amr earned M.Sc. and Ph.D. degrees from Imperial College, University of London, and his Bachelor of Science degree from Cairo University.



## THE HONORABLE KENT R. HANCE

Hance Scarborough, L.L.P.

[@KentRHance](#)

Kent R. Hance is native of Dimmitt, Texas and the founding partner of the law firm Hance Scarborough, L.L.P. Hance earned a B.B.A. from Texas Tech University and a law degree from the University of Texas. He's been practicing law since 1968, and has served the public as a State Senator, U.S. Congressman, and Texas Railroad Commissioner. From 2006 to 2014, Hance served his alma mater as Chancellor of the Texas Tech University System, helping raise more than \$1.2 billion and increasing the system's student enrollment by 45%. Hance currently serves as Chancellor Emeritus of Texas Tech and works at his law firm representing various clients, including those in the healthcare industry, in Texas and Washington, D.C.



## THE HONORABLE KELLY HANCOCK

Texas State Senator, Chair,


Senate Committee on Business & Commerce

[@KHancock4TX](#)

First elected to the Texas Senate in 2012, Kelly Hancock represents portions of Tarrant and Dallas Counties in Senate District 9. He previously served three terms in the Texas House of Representatives and 13 years on his local school board. In both legislative chambers, Hancock has advocated for core conservative and pro-business values of limited government and lower taxes.

Hancock serves as Chairman of the Senate Committee on Business & Commerce, which oversees all health insurance legislation, and sits on the state's Legislative Budget Board. He additionally serves as Presiding Officer of the Partnership Advisory Commission, Vice Chairman of the Senate Transportation Committee, and as a member of the Natural Resources & Economic Development Committee, the Property Tax Committee, the budget-writing Finance Committee, the Select Committee on Mass Violence Prevention Community Safety, the Select Committee on Redistricting, and the Texas Privacy Protection Advisory Council.

A graduate of Baylor University, Hancock possesses an extensive business background and runs his family-founded distribution company. He and his wife, Robin, have been married more than 30 years and have three adult children and one grandchild.



## **TOM KOWALSKI**

**President and CEO**

**Texas Healthcare and Bioscience Institute (THBI)**

Thomas R. Kowalski is President and CEO of the Texas Healthcare and Bioscience Institute (THBI) in Austin, Texas.

He has previously served as a senior staff member to Governor Bill Clements of Texas, U.S. Senator John Tower of Texas, and Congressman Jim Collins of Dallas, Texas.

With over thirty-five years of political and policy experience, Mr. Kowalski was appointed in 1989 by Governor Bill Clements to the Board of Regents of the Texas State University System. He served as Chairman of the Board of Regents in 1995. In addition, Mr. Kowalski currently serves as Chairman of the McCoy College of Business Administration Advisory Council at Texas State University.

An avid public speaker, Mr. Kowalski gives numerous talks on positioning Texas as a global leader in the development of biotechnology and life sciences. He was appointed in 2002 to Governor Rick Perry's State Council on Science and Biotechnology Development. He is the former Chairman of Bio's Council of State Biotechnology Associations, whose national membership consists of forty-nine state associations involved in biotechnology development and advocacy. Mr. Kowalski is a distinguished alumni of Texas State University.

A lifelong Texan, Mr. Kowalski resides in Austin, Texas with his wife, Susie.



## **DR. DAVID LAKEY**

**Vice Chancellor for Health Affairs and**

**Chief Medical Officer**

**The University of Texas System**

[@DavidLakey\\_MD](#)

David Lakey, M.D. serves as the Vice Chancellor for Health Affairs and Chief Medical Officer at The University of Texas System, and as Senior Advisor to the President and Professor of Medicine at The University of Texas Health Science Center Tyler. Dr. Lakey was the Commissioner of the Texas Department of State Health Services from 2007 to 2015. Prior to being appointed commissioner, Dr. Lakey served as the chief of the Division of Clinical Infectious Disease and medical director of the Center for Pulmonary and Infectious Disease Control at the University of Texas Health Center in Tyler. Dr. Lakey is a graduate from Rose Hulman Institute of Technology, Indiana University School of Medicine, and completed his internal medicine, pediatrics, and infectious disease training at Vanderbilt University Medical Center.



## **DR. KRISTOFOR LANGLAIS**

Biomedical Policy Analyst and  
Genomics Program Lead  
National Institutes of Health (NIH)

Kristofor Langlais, Ph.D., is a senior Federal health science policy expert at the National Institutes of Health (NIH). He leads the Genomics and Health Program within

the NIH Director's Office of Science Policy (OSP), which addresses emerging, high-impact issues of importance to the biomedical research enterprise and the U.S. Government. In this role, Dr. Langlais provides leadership in the development and oversight of policies and initiatives that advance the NIH Director's priorities in the areas of genomic medicine and data sharing. Dr. Langlais employs subject matter expertise in the molecular biosciences and public policy to develop NIH input on proposed regulations and legislation that impact the oversight and implementation of molecular diagnostics and genomic medicine. He played a key role in the development of the NIH Genomic Data Sharing Policy and leads cross-disciplinary teams to address emerging privacy concerns that arise with new technologies. Prior to joining OSP in 2011, Dr. Langlais completed a postdoctoral fellowship at the National Institute of Child Health and Human Development, NIH, performing high-impact research on epigenetic regulation of gene expression during embryonic development. Dr. Langlais received his Ph.D. in molecular and cellular biology from the Oregon Health & Science University School of Medicine.



## THE HONORABLE TOM OLIVERSON, M.D.

Texas House of Representatives

[@TomOliverson](#)

Dr. Tom Oliverson represents Texas' 130th State House District in northwest Harris County, including the communities of Tomball, Cypress, Waller, and Hockley.

He serves on the Calendars, Natural Resources, and Insurance committees in the Texas Legislature and is a member of the House Republican Caucus Policy Committee.

His successful first session culminated with his being chosen by his Republican colleagues as "Best Freshman Legislator" of the 85th legislative session. In his second session, he was named by Texas Monthly as one of the "best legislators of the 86th session". Dr. Oliverson has authored legislation on a diverse set of issues including: surprise medical billing, drug pricing transparency, and free-standing emergency rooms. He is also active with the National Council of Insurance Legislators (NCOIL), where he serves as the Vice Chair of the Health Insurance, Long Term Care, and Health Retirement Committee and as a member of the Executive Committee.

In his professional career, Dr. Oliverson is a board-certified anesthesiologist and partner in US Anesthesia Partners, the largest anesthesia group in Texas. He and his wife Jennifer live in Cypress with their three children.



## **LORI M. REILLY, ESQ.**

Chief Operating Officer  
Pharmaceutical Research and  
Manufacturers of America (PhRMA)

[@lreilly71](#)

Lori M. Reilly is chief operating officer at the Pharmaceutical Research and Manufacturers of America (PhRMA), providing executive level management, leadership and strategic direction for the organization. In this role, Ms. Reilly oversees PhRMA's advocacy activities, including its federal, state and international government affairs and alliance development work. Ms. Reilly works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients.

Ms. Reilly has nearly two decades of experience at PhRMA; prior to her current role, Ms. Reilly was the executive vice president of policy, research and membership at PhRMA, leading the development and implementation of legislative, regulatory and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee.

Ms. Reilly received a B.A. in political science from the University of Nebraska-Lincoln where she graduated with honors, and a J.D. from the University of Nebraska College of Law. She currently resides in Alexandria, Virginia with her husband and their four children.



## DR. EDWARD RUDNIC

CEO

DisperSol Technologies

Edward M. Rudnic, PhD, is the Chief Executive Officer of DisperSol Technologies, a private biopharma in Georgetown, Texas.

Dr. Rudnic was founder, chairman and CEO of MiddleBrook Pharmaceuticals (Nasdaq: MBRK, previously Advancis; Nasdaq: AVNC), where he founded the company, and took it public on the NASDAQ. Prior to founding MiddleBrook, he was Senior Vice President, Development and Technical Operations for Shire, where he led all U.S. clinical and research activities. He was the lead inventor of Carbatrol/Equetro with cumulative sales of over \$1 billion to date, and co-inventor of Adderall XR with cumulative sales of over \$18 billion to date. Additionally, he served as COO, then CEO of QRx Pharma, a public Australian biopharma (QRX:ASX).

He began with management roles with increasing responsibility at Merck and at Bristol Myers-Squibb. He has been named as inventor of 55 issued U.S. patents, and numerous international patents. Dr. Rudnic has acted in numerous consulting capacities to FDA, Health Canada, NIH, and the pharmaceutical industry. Dr. Rudnic holds a B.S. in Pharmacy, a M.S. in Pharmaceuticals, and a PhD in Pharmaceutical Sciences from the University of Rhode Island.



## DR. LARRY SCHLESINGER

President and CEO

Texas Biomedical Research Institute

[@txbiomed](https://twitter.com/txbiomed)

Larry S. Schlesinger, MD is an internationally recognized authority in infectious diseases. He began his distinguished scientific leadership career after joining the faculty at the University of Iowa in 1991 where he served as Fellowship Director for the Division of Infectious Diseases and Associate Chair of the Department of Medicine. He moved to the Ohio State University in 2002 where he served as Director of the Division of Infectious Diseases, Department of Internal Medicine until 2011, when he became first chair of the Department of Microbial Infection & Immunity. In 2017, he became President/CEO of Texas Biomedical Research Institute in San Antonio, Texas. Dr. Schlesinger is a practicing scientist whose passion lies in the development of people and programs that will have revolutionary impact on human health for years to come.

Dr. Schlesinger is a leading physician scientist whose studies focus on the pathogenesis of tuberculosis and other airborne infectious agents that subvert lung immune mechanisms. He is a recent NIH NIAID Council member, Fellow of the American Association for the Advancement of Science, Infectious Diseases Society of America, Association of American Physicians and American Academy of Microbiology.





## **THE HONORABLE JOHN ZERWAS, M.D.**

**Executive Vice Chancellor for Health Affairs  
The University of Texas System**

[@RepJohnZerwas](#)

John M. Zerwas, M.D., joined The University of Texas System as Executive Vice Chancellor for Health Affairs in October 2019. He provides oversight and guidance for the six UT System health institutions, one of the largest networks of academic health institutions in the country with an aggregate annual operating budget of more than \$14.7 billion. Prior to joining U. T. System, he served the citizens of Texas House District 28 (Northwestern Fort Bend County) for seven legislative terms in the Texas House of Representatives, earning numerous accolades for his dedication to public service.

A physician for more than 30 years, Zerwas is past president of the American Society of Anesthesiologists. He cofounded a Houston area group practice in 1996 which became part of US Anesthesia Partners in 2012. From 2003 to 2008, Zerwas served as Chief Medical Officer of the Memorial Hermann Hospital System, and as Chief Physician Integration Officer until 2009.

Zerwas graduated from Bellaire High School in 1973, and in 1978, he married his late wife Cindy Hughes. After graduating from the University of Houston, he earned his Doctorate in Medicine at Baylor College of Medicine. John, together with his wife Sylvia, have six children and eight grandchildren.

## THANK YOU SUMMIT SPONSORS



*\*Complete list at time of publishing*



**SAVE THE DATE**

**THBI SUMMIT, LUMINARY DINNER,  
AND LIFE SCIENCE EXPO**

**SEPTEMBER 28, 2020**

LUMINARY DINNER AND EXPO  
AT&T Executive Education and Conference Center

POLICY SUMMIT  
Texas Capitol

Austin, Texas

**WE HOPE TO SEE YOU THERE!**





# TEXAS HEALTHCARE AND BIOSCIENCE SUMMIT

## THANK YOU FOR JOINING US!

 [facebook.com/txhbi](https://facebook.com/txhbi)

 [@TXHBI](https://twitter.com/TXHBI)

#THBISUMMIT



WWW.THBI.COM | 512-708-8424  
807 BRAZOS STREET, SUITE 607, AUSTIN, TX 78701